Back to Search
Start Over
Dipyridamole-thallium/sestamibi before vascular surgery: a prospective blinded study in moderate-risk patients.
- Source :
-
Journal of vascular surgery [J Vasc Surg] 2000 Jul; Vol. 32 (1), pp. 77-89. - Publication Year :
- 2000
-
Abstract
- Purpose: This study assessed in a prospective, blinded fashion whether a reversible defect on dipyridamole-thallium (DTHAL)/sestamibi (DMIBI) can predict adverse cardiac events after elective vascular surgery in patients with one or more clinical risk factors.<br />Methods: Consecutive patients with one or more clinical risk factors underwent a preoperative blinded DTHAL/DMIBI. Patients with recent congestive heart failure (CHF) or myocardial infarction (MI) or severe or unstable angina were excluded.<br />Results: Eighty patients (78% men; mean age, 65 years) completed the study. Diabetes mellitus was the most frequent clinical risk factor (73%), followed by age older than 70 years (41%), angina (29%), Q wave on electrocardiogram (26%), history of CHF (7%), and ventricular ectopy (3%). The results of DTHAL/DMIBI were normal in 36 patients (45%); a reversible plus or minus fixed defect was demonstrated in 28 patients (36%), and a fixed defect alone was demonstrated in 15 patients (19%). Nine adverse cardiac events (11%) occurred, including three cases of CHF, and one case each of unstable angina, Q wave MI, non-Q wave MI, and cardiac arrest (successfully resuscitated). Two cardiac deaths occurred (2% overall mortality), one after a Q wave MI and one after CHF and a non-Q wave MI. The cardiac event rate was 14% for reversible defect and 9.8% without reversible defect (P =.71). The cardiac event rate was 12.5% (one of eight cases) for two or more reversible defects, versus 11.1% (eight of 72 cases) for fewer than two reversible defects (P = 1.0). The sensitivity rate of two or more areas of redistribution was 11% (95% CI, 0.3%-48%), the specificity rate was 90%, and the positive and negative predictive values were 12.5% and 89%, respectively.<br />Conclusion: Our study demonstrated no association between reversible defects on DTHAL/DMIBI and adverse cardiac events in moderate-risk patients undergoing elective vascular surgery.
- Subjects :
- Aged
Female
Humans
Male
Predictive Value of Tests
Prospective Studies
Radionuclide Imaging
Risk Assessment
Sensitivity and Specificity
Dipyridamole
Heart Diseases diagnostic imaging
Postoperative Complications diagnostic imaging
Radiopharmaceuticals therapeutic use
Technetium Tc 99m Sestamibi
Thallium Radioisotopes
Vascular Surgical Procedures
Vasodilator Agents
Subjects
Details
- Language :
- English
- ISSN :
- 0741-5214
- Volume :
- 32
- Issue :
- 1
- Database :
- MEDLINE
- Journal :
- Journal of vascular surgery
- Publication Type :
- Academic Journal
- Accession number :
- 10876209
- Full Text :
- https://doi.org/10.1067/mva.2000.107311